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Objectives The goal of this study was to demonstrate the enhancement of human cardiac progenitor cell (hCPC) reparative
and regenerative potential by genetic modification for the treatment of myocardial infarction.
Background Regenerative potential of stem cells to repair acute infarction is limited. Improved hCPC survival, proliferation,
and differentiation into functional myocardium will increase efficacy and advance translational implementation
of cardiac regeneration.
Methods hCPCs isolated from the myocardium of heart failure patients undergoing left ventricular assist device implanta-
tion were engineered to express green fluorescent protein (hCPCe) or Pim-1-GFP (hCPCeP). Functional tests of
hCPC regenerative potential were performed with immunocompromised mice by using intramyocardial adoptive
transfer injection after infarction. Myocardial structure and function were monitored by echocardiographic and
hemodynamic assessment for 20 weeks after delivery. hCPCe and hCPCeP expressing luciferase were observed
by using bioluminescence imaging to noninvasively track persistence.
Results hCPCeP exhibited augmentation of reparative potential relative to hCPCe control cells, as shown by significantly
increased proliferation coupled with amelioration of infarction injury and increased hemodynamic performance
at 20 weeks post-transplantation. Concurrent with enhanced cardiac structure and function, hCPCeP demon-
strated increased cellular engraftment and differentiation with improved vasculature and reduced infarct size.
Enhanced persistence of hCPCeP versus hCPCe was revealed by bioluminescence imaging at up to 8 weeks
post-delivery.
Conclusions Genetic engineering of hCPCs with Pim-1 enhanced repair of damaged myocardium. Ex vivo gene delivery
to modify stem cells has emerged as a viable option addressing current limitations in the field. This study
demonstrates that efficacy of hCPCs from the failing myocardium can be safely and significantly enhanced
through expression of Pim-1 kinase, setting the stage for use of engineered cells in pre-clinical settings.
(J Am Coll Cardiol 2012;60:1278–87) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.047The human heart harbors an adult stem cell population
consistent with true characteristics of stemness such as
self-renewal (1), clonogenicity (2), and multilineage differ-
entiation potential (3). These “cardiac stem cells” populate
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2012, accepted April 2, 2012.the heart in highly conserved atrial and ventricular niches
that regulate myocyte turnover (4). Recent evidence dem-
onstrates the ability of resident human cardiac cells to
differentiate into mechanically integrated cardiomyocytes
(3,5) as well as vascular smooth muscle and endothelial cells,
thereby supporting cardiac regeneration (6). Adoptive trans-
See page 1288
fer of human cardiac stem cells results in modest repair due
in part to lack of survival, proliferation, and commitment of
the transplanted cells after myocardial infarction. Therapeu-
tic stem cell performance is further complicated by the
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October 2, 2012:1278–87 Human Cardiac Progenitor Cells With Pim-1 Improve Heart Repairpossesses a stem cell pool adversely affected by age concomitant
with up-regulation of senescence markers (4), shorter telomere
ength (3), and decreased metabolic activity (7). These detrimen-
al insults collectively compromise the regenerative ability of
tem cells in this aged population, limiting their use for
utologous therapy.
Modification of human cardiac progenitor cells (hCPCs)
o enhance proliferation, survival, and commitment in-
reases effectiveness and buttresses use of stem cells as a
iable therapeutic modality. Ex vivo genetic modification is
n effective strategy to enhance stem cell function (8,9).
reviously, our group has shown that Pim-1 kinase, a
ownstream effector of Akt, enhances cell survival (10) and
etabolic activity (11), attenuates apoptosis (12), and main-
ains mitochondrial integrity (11,13). Mechanistically, apo-
totic proteins such as Bad (14) and cell cycle proteins
ncluding p21 (15) have been identified as Pim-1 substrates.
n the heart, Pim-1 is induced as a consequence of stress or
athological insult (10). Pim-1 also positively regulates
eovasculogenesis (16), which forms an integral part of the
yocardial repair response. Proof-of-principle studies per-
ormed with murine CPCs in a syngeneic system demon-
trate that Pim-1 augments reparative processes after myo-
ardial injury, with improved cellular survival, persistence,
nd differentiation of engrafted cells into cardiac lineages 32
eeks after transplantation (17). However, potentiation of
CPCs derived from patients who have heart failure pres-
nts a different challenge from the healthy young CPCs
sed in syngeneic murine studies. Utility of hCPCs as a
iable therapeutic option would be further improved by
nterventional strategies designed to overcome inherent
imitations in aged or pathologically challenged myocardial
issue.
Applicability of genetic modification to the clinical set-
ing requires progression into an experimental model with
CPCs obtained from the target population of aged patients
ho would be candidates for regenerative therapy: individ-
als undergoing left ventricular assist device implantation as
bridge to transplant or destination therapy. In the present
tudy, we demonstrate that hCPCs isolated from failing
yocardium and modified with Pim-1 possess enhanced
eparative potential relative to control hCPCs. Improve-
ents mediated by hCPCs modified with Pim-1 were
vident structurally and functionally, with durable human
ellular persistence, engraftment, and acquisition of pheno-
ypic characteristics consistent with differentiated myocar-
ium. These results validate the utility of Pim-1 kinase as a
olecular interventional approach to enhance hCPC-
ediated regeneration, even when derived from a failing
uman heart.
ethods
ee the Online Appendix for an explanation of the study
ethods. hesults
im-1 overexpression character-
zation in hCPCs. hCPCs are
egative for hematopoietic markers
D34, CD45, CD2, CD16, and
D31 and are positive for c-kit
Online Figs. 1A and 1B). Human
ardiac progenitor cells overexpress-
ng green fluorescent protein
hCPCe) and human cardiac pro-
enitor cells overexpressing Pim-1
hCPCeP) were transduced with
entiviral vectors Lv-egfp and Lv-
gfppim1 (Online Fig. 1C). Effi-
iency of modification after lentiviral
ransduction was 74.25% and
5.95% for hCPCe and hCPCeP,
espectively, as measured by using
ow cytometric analyses for en-
anced green fluorescent protein
eGFP) (Online Fig. 1D). Expres-
ion of eGFP and Pim-1 in hCPCe
nd hCPCeP was confirmed by using immunoblot analysis
Online Fig. 1E). Karyotype analyses revealed normal chromo-
ome content in either hCPCe or hCPCeP, indicating normal
itotic chromosomal segregation in the genetically engineered
ells (Online Fig. 1F).
nhanced proliferation, mitochondrial activity, and TRAP-
ctivity in hCPCeP. Proliferation was increased in hCPCeP
elative to hCPCs and hCPCe (p  0.001) at day 3 as
easured by using CyQUANT assay (Fig. 1A). Conversely,
sing the Pim-1 pharmacological blocker quercetagetin,
roliferation was abrogated at day 1 (p  0.01) and day 3
p  0.001), demonstrating involvement of Pim-1 in the
roliferative response (Fig. 1B). hCPCeP also showed
ncreased metabolic activity compared with hCPCs and
CPCe at day 3 (p  0.001), as measured by using MTT
ssay (Fig. 1C). Similarly, relative telomerase reverse tran-
criptase activity measured by using a TRAP assay was
ignificantly improved (p  0.05) in hCPCeP compared
ith hCPCe (Fig. 1D). Increased levels of phospho-p21, a
im-1 target substrate, confirm functional activity of ex-
ressed Pim-1 protein by using immunoblot analysis
Figs. 1E and 1F). Collectively, these results indicate that
im-1 modification of hCPC confers phenotypic properties
onsistent with beneficial cellular signaling.
ncreased cardiac commitment of hCPCeP after dexa-
ethasone differentiation. Markers of cardiogenic lineage
ommitment, including MEF2C, von Willebrand factor
vWF), and GATA-6, were up-regulated in hCPCeP
elative to hCPCe after dexamethasone (Dex) treatment, as
onfirmed by using quantitative real-time polymerase chain
eaction analysis (Fig. 2A) and immunocytochemistry
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increases in immunolabeling for all 3 markers as well as
morphological remodeling of hCPCe and hCPCeP after
Dex exposure (Fig. 2C). Morphological remodeling (flatten-
ing) of cells treated with Dex was consistent with previous
findings (17–19). These results indicate augmentation of lin-
eage commitment signals in hCPCeP relative to control
hCPCe after rudimentary differentiation induction with Dex.
hCPCeP augment cardiac function and reduce infarct
size. Delivery of hCPCeP, hCPCe, or vehicle alone by
intramyocardial injection into SCID mice concurrent with
myocardial infarction was performed to determine repara-
tive potential. Loss of function in all groups indicated
comparability of infarction damage as assessed at 1 week
post-challenge by using echocardiography (Figs. 3A and 3B).
ithin 4 weeks after cell injection, myocardial function was
ignificantly improved (p  0.001) (Online Table S3) in
earts of mice receiving either hCPCe or hCPCeP com-
ared with vehicle, as measured via echocardiographic
ssessment of ejection fraction (EF) or fractional shortening
FS) (Figs. 3A and 3B). Differences in myocardial function
etween hCPCe and hCPCeP 4 weeks after transplantation
ere not significant (p  0.05) (Online Table S1). However,
Figure 1 Enhancement of Proliferation, Mitochondrial Activity,
(A) CyQUANT assay: human cardiac progenitor cells overexpressing Pim-1 (hCPCeP
(hCPCs) and human cardiac progenitor cells overexpressing green fluorescent prot
quercetagetin show decreased proliferation relative to nontreated hCPCeP (n  4)
improved metabolic activity relative to hCPC and hCPCe (n  4). (D) Telomerase r
(n  3). (E) Immunoblot analysis for p21 and p-p21. (F) Quantitation of immunobF and FS performance improved in the hCPCeP group from 4o 8 weeks post-delivery, in contrast with depressed contractility
or hCPCe-treated mice that was not significantly different (p
.05) from the vehicle group (Figs. 3A and 3B). Myocardial
ontractile performance of hearts receiving hCPCeP in-
reased by 1.81-fold in EF and 1.86-fold in FS compared
ith hCPCe 20 weeks after transplantation. Hemodynamic
arameters were also significantly improved in hCPCeP-
reated hearts compared with those treated with hCPCe
p  0.01) or vehicle (p  0.001) 20 weeks after transplan-
ation. hCPCeP-treated hearts increased dP/dtmax and dP/dtmin
(maximum and minimum rate of pressure change in the
ventricle) by 1.29-fold and 1.23-fold, respectively (Fig. 3C)
together with a 1.37-fold increase in left ventricular devel-
oped pressure (Fig. 3D) relative to hCPCe. Collectively,
these results demonstrate the enhanced capacity of hCPCeP
to preserve and/or restore myocardial function after infarc-
tion injury.
Enhancement of myocyte formation and neovasculariza-
tion resulting from hCPCeP delivery. Improvement of
hemodynamic performance in hearts receiving hCPCeP
(Fig. 3) was accompanied by evidence of cardiogenic lineage
commitment. Cardiomyocyte immunoreactivity with alpha-
sarcomeric actin labeling in hearts receiving hCPCeP dem-
elomerase Activity in hCPCeP
bited enhanced proliferation compared with human cardiac progenitor cells
PCe) for 3 days (n  4). (B) CyQUANT assay: hCPCeP treated with 10 M of
etabolic activity measured by using MTT reagent: hCPCeP demonstrated
transcriptase (TERT) activity is significantly higher in hCPCeP relative to hCPCe
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October 2, 2012:1278–87 Human Cardiac Progenitor Cells With Pim-1 Improve Heart Repairdent eGFP signal indicative of derivation from hCPCeP.
Human origin of cells in myocardial sections from mice was
evident by immunolabeling for eGFP co-localized with
human-specific mitochondrial marker or by detection of
characteristic repetitive Alu DNA sequence (Online Fig. 2).
CPCeP displayed a significant 2.32-fold increase (p 0.05) in
elomere length after adoptive transfer to infarcted hearts
elative to hCPCe 20 weeks after transplantation, consistent
ith a youthful cellular phenotype (Figs. 4A to 4C).
nfarction size was significantly smaller at 20 weeks in
CPCeP-transplanted mice compared with hCPCe-
ransplanted mice. Infarction damage involving 61.3% of
he left ventricular free wall in hearts receiving hCPCeP
ompared favorably with 84.3% in hearts receiving hCPCe
p  0.05). Infarct size was not significantly different in
earts receiving either vehicle or hCPCe (Figs. 4D and 4E).
resence of c-kit/GFP cells derived from the adoptively
ransferred population increased 4.0-fold in hearts receiving
CPCeP relative to hCPCe 12 weeks after delivery. Total
-kit cell number was significantly higher by 1.75-fold
p 0.05) in heart sections from hCPCeP relative to hearts
eceiving hCPCe at 12 weeks (Figs. 4F to 4I). New myocyte
ormation in these hearts was identified according to eGFP
ignal together with alpha-sarcomeric actin staining 12
eeks after transplantation (Fig. 5A). New vessel formation
as evident by coincidence of eGFP immunolabeling with
mooth muscle actin (SM22) to label vascular walls as well
s vWF to label endothelial vessel lining (Figs. 5B to 5C).
yocardial sections from hearts receiving hCPCeP exhibited
8% GFP/SM22 cells versus 17% in hCPCe (Fig. 5D).
imilarly, hCPCeP-treated hearts possessed 22% GFP/
WF cells compared with 12% in hCPCe. Expression of
Figure 2 Increases in Cardiac Commitment of hCPCeP After De
(A) Quantitative real-time polymerase chain reaction analysis for hCPCe and hCPC
(vWF) (n  3). *p  0.05, **p  0.001, ***p  0.01, hCPCeP-Dex versus hCPC
staining for MEF2C (cardiac), vWF (endothelial), and GATA-6 (smooth muscle) befo
tions as in Figure 1.im-1 was maintained for at least 12 weeks after delivery mith increased immunolabeling for Pim-1 (Online Fig. 3).
ollectively, these results suggest the enhanced ability of
CPCeP to survive and proliferate, significantly aug-
enting angiogenesis and myogenesis in the infarcted
eart.
ersistence of hCPCeP after delivery confers long-term
emodynamic performance improvement revealed by non-
nvasive imaging. hCPC persistence in vivo was longitudi-
ally assessed over an 8-week period by using biolumines-
ence imaging (BLI) of luciferase (Luc) signal in hearts
eceiving either hCPCe or hCPCeP transduced with Luc
eporter construct (Fig. 6A) immediately after infarction
njury. Both hCPCe-Luc or hCPCeP-Luc produced a
obust BLI signal at day 2 in all recipient animals, indicative
f successful cell delivery to the heart. The BLI signal
emained detectable in the hCPCeP-Luc cohort throughout
6 days post-delivery (Figs. 6B and 6C), in stark contrast to
oss of signal by 14 days after delivery in the hCPCe-Luc
roup. These results suggest the superior persistence of
CPCeP-Luc after delivery, particularly in the critical
indow of 2 to 4 weeks post-infarction.
Myocardial contractile performance impairment was ini-
ially comparable shortly after cardiomyopathic challenge in
ohorts of hCPCe-Luc or hCPCeP-Luc, indicative of similar
nfarction injury according to echocardiographic assessment.
ubsequently, mice receiving hCPCeP-Luc exhibited im-
rovement in FS, left ventricular end-diastolic dimension, left
entricular end-systolic dimension, and anterior wall thickness
t 8 weeks post-injury (Figs. 7A to 7D) (p  0.05).
agnetic resonance imaging at 1 and 8 weeks post-
nfarction substantiated the echocardiographic results, re-
ealing improved hemodynamic parameters at 8 weeks in
fferentiation
er dexamethasone (Dex) treatment for MEF2C, GATA-6, and von Willebrand factor
ex; #p  0.05, ##p  0.01, hCPCeDex versus hCPCePDex. (B, C) Immuno-
after Dex treatment for 7 days. GFP  green fluorescent protein; other abbrevia-x Di
eP aft
ePD
re andice receiving hCPCeP-Luc compared with hCPCe-Luc
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diastolic volume, left ventricular end-systolic volume, and
EF (p  0.05). P values for all parameters by magnetic
resonance imaging or echocardiography are provided
(Online Table S4). hCPCeP-Luc–treated hearts exhibited a
22.5% increase in anterior wall dimension with a 10%
decrease in left ventricular end-diastolic dimension and a
20.6% decrease in left ventricular end-systolic dimension by
echocardiography 8 weeks after transplantation relative to
hCPCe-Luc.
Discussion
Discovery of hCPCs contributing to cardiomyogenesis
within the heart and supporting myocardial repair has
revolutionized the conceptual view of treatment for heart
disease, as supported by the capacity of hCPCs to form
functionally integrated cardiomyocytes and vasculature
Figure 3 Improvement of Cardiac Performance of Mice Treated
(A, B) Percentage of fractional shortening (FS) and ejection fraction (EF) measured by
n  16. (C) Hemodynamic assessment of rate of rise of left ventricular pressure
hCPCeP: n  5). (D) Left ventricular developed pressure (LVDP). *p  0.05, **p
p  0.01, for hCPCe versus hCPCeP; #p  0.01, ##p  0.001, ###p  0.0(20). However, survival and persistence of adoptivelytransferred hCPCs used for therapeutic purposes remain
a major concern, particularly when the donor cell popu-
lation used for autologous therapy is derived from patho-
logically stressed myocardium. Regenerative capabilities
of adult hCPCs are likely to be impaired by age (21) and
disease (22), limiting the reparative and regenerative
potential of these autologously derived cells. Ex vivo
modification or pre-conditioning has been shown to
prime adoptively transferred cells for myocardial repair
(23,24). Genetic modification to augment cellular sur-
vival and proliferation is a viable molecular interventional
strategy, as previously published by our group, for syn-
geneic murine CPCs (17,25). The present study ad-
dresses a critical issue by demonstrating that Pim-1
modification augments regenerative and reparative po-
tential of hCPC derived from heart failure patients,
bringing this conceptual approach another step closer to
hCPCeP 20 Weeks After Transplantation in SCID Mice
echocardiography; sham: n  6; vehicle: n  12; hCPCe: n  16; and hCPCeP:
) after cell transplantation (sham: n  3; vehicle: n  5; hCPCe: n  5; and
01, ***p  0.01, for vehicle versus hCPCeP; p  0.05, p  0.001,
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modification with Pim-1 also display phenotypic character-
istics consistent with enhanced survival, proliferation, and
reversal of senescent characteristics. hCPCeP exhibit high
proliferation and metabolic activity in vitro (Figs. 1A to
1C). Telomere lengths of hCPCeP are also preserved,
suggesting an important role of Pim-1 in maintaining telomere
length (Fig. 1D) to antagonize cellular senescence; this topic is
currently being investigated by our group. Pim-1 also increases
phosphorylation of p21 (Figs. 1E and 1F), a cyclin-dependent
kinase inhibitor, as well as stabilizing c-Myc and the nuclear
mitotic apparatus (26). Increased survival of Pim-1–
engineered cells is likely due to the ability of the kinase to
promote proliferation and attenuate apoptotic signaling
(10,27), moderating enhanced proliferation and persistence of
the transplanted cells to augment the reparative process.
Potentiation of hCPCs from heart failure patients under-
going left ventricular assist device implantation reported in
Figure 4 hCPCeP Show Increases in Telomere Length, Enhance
(A) Remote and (B) infarct zone telomere length in mice treated with hCPCeP, tel
mere length of hCPCe and hCPCeP (p  0.05). (D) Masson’s trichrome staining fo
ventricular free wall (LVFW) in vehicle, hCPCe, and hCPCeP (n  3), p  0.01. (F,
nuclei 24 (blue) in hCPCe and hCPCeP, respectively. (H) Quantitation of total num
c-kit cells/mm2 in hCPCe- and hCPCeP-treated animals (n  3). *p0.05, **pour study addresses the heretofore critical unanswered issueof whether aged hCPCs from pathologically damaged
myocardium would retain the capacity to benefit from
genetic engineering. Indeed, heart failure associated with
aging has been proposed to be a “stem cell disease” charac-
terized by impaired functional reserve of the endogenous
stem cell pool due to exhaustion, senescence, depletion, or
inability to cope with the environmental stressors (28).
Recent clinical results using autologous hCPCs to restore
myocardial performance in the SCIPIO (Cardiac Stem Cell
Infusion in Patients With Ischemic Cardiomyopathy) trial
found that the c-kit cell population is capable of mediat-
ing improvement in both EF as well as reduction in infarct
size (29). With unequivocal evidence of clinical relevance for
the treatment of heart failure using c-kit hCPC, the
future of hCPC therapy will inevitably turn toward assess-
ment of approaches to enhance the regenerative process.
Can Pim-1 be considered an appropriate molecular in-
terventional strategy for enhancing cardiogenesis? Pim-1
t of c-kit–Positive Cell Number, and Decreases in Fibrosis
(white), GFP (green), desmin (red), and nuclei (blue). (C) Quantitation of telo-
cle-, hCPCe-, and hCPCeP-injected SCID mice. (E) Percentage of infarcted left
munostaining for c-kit (white), GFP (green), alpha-sarcomeric actin (red), and
c-kit cells/mm2 in vehicle, hCPCe, and hCPCeP. (I) Quantitation of GFP and





0.01,induces proliferation of endothelial (16) and vascular
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commitment as evidenced by increased expression of car-
diogenic transcripts in Pim-1– engineered CPCs (17)
(Fig. 2). hCPCeP express vWF transcript before and after
differentiation in vitro and after transplantation into dam-
aged myocardium. Moreover, clear evidence of myocytes
derived from adoptively transferred hCPCeP was revealed
after 20 weeks post-delivery by using immunohistochemis-
try (Fig. 5, Online Fig. 2). Persistence, expansion, and
integration of the hCPCeP into myocardial tissue translate
Figure 5 hCPCeP Augment Myocardial Repair 12 Weeks After
Immunolabeling for (A) GFP (green), alpha-sarcomeric actin (red), and nuclei (blu
vW (white), GFP (green), alpha-sarcomeric actin (red), and nuclei (blue). (D) Qua
Boxes indicate enlarged areas. Scale bars  150 m for all panels except row A,
tions as in Figures 1, 2, and 4.into progressive improvement in myocardial structure andfunction evident up to 20 weeks post-delivery relative to
hCPCe (Figs. 3 and 6). The durability of repair, together
with the superior improvement of functional parameters of
myocardial hemodynamic performance, supports the use of
Pim-1 as a plausible molecular strategy to enhance myocar-
dial regeneration with modified hCPCs.
Despite pro-proliferative effects mediated by Pim-1, on-
cogenic transformation has never been observed in any of
our human samples, and all engineered hCPCeP were
amenable to differentiation in vitro that resulted in acqui-
plantation
SM22 (white), GFP (green), alpha-sarcomeric actin (red), and nuclei (blue). (C)
n of SM22, vWF and alpha-sarcomeric actin in hCPCe and hCPCeP (p  0.001).
hCPCe and hCPCeP widefield images  50 m and insets  25 m. Abbrevia-Trans
e). (B)
ntitatio
wheresition of post-mitotic characteristics (Fig. 2). In vivo studies
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October 2, 2012:1278–87 Human Cardiac Progenitor Cells With Pim-1 Improve Heart Repairshow cardiogenic commitment of hCPCeP to all 3 essential
cell lineages for reconstitution of myocardial tissue: cardio-
myocytes, vasculature, and endothelium (Fig. 5). Further-
more, karyotypic analyses show normal chromosome con-
tent in hCPCeP (Online Fig. 1F). Although oncogenic risk
needs to be carefully evaluated when genetic engineering is
proposed, it is important to consider that lentiviral vectors
have also made their way into clinics as therapies (31),
including for advanced forms of HIV infections (32),
Parkinson’s disease (33), and inherited disorders affecting
hematopoietic cells (34). In addition, lentiviral vectors have
integration sites away from transcriptional regulatory sites,
making them a safe therapeutic option (35). These findings
are in stark contrast to published literature showing chro-
mosomal abnormalities in certain embryonic stem cells and
induced pluripotent stem cells in which oncogenic transfor-
mation remains a significant barrier to therapeutic imple-
Figure 6 Enhancement of hCPCeP Persistence
(A) Firefly luciferase (Luc) reporter construct. (B) Bioluminescence imaging (BL
hCPCe-Luc (top) and hCPCeP-Luc (bottom) after myocardial infarction. hCPCe-L
shows signal throughout the experimental cohort for 56 days. (C) Quantitation
tions as in Figure 1.mentation (36,37).Clinical trials using bone marrow–derived stem cells
(TAC-HFT [Transendocardial Injection of Autologous
Human Cells (bone marrow or mesenchymal) in Chronic
Ischemic Left Ventricular Dysfunction and Heart Failure
Secondary to Myocardial Infarction]) (38) and hCPCs (29)
effectively demonstrate improved cardiac function after
transplantation of stem cells. Narrow inclusion criteria for
these clinical trials leave open the issue as to whether
initially promising findings will be broadly applicable to the
much greater segment of patients experiencing the debili-
tating consequences of aging and multiple concurrent car-
diac problems. Nevertheless, despite severe deterioration of
myocardium necessitating surgical intervention and me-
chanical assist device implantation in the 68-year-old source
of our hCPC, Pim-1 expression effectively increased myo-
cardial repair in immunosuppressed murine recipients,
whereas hCPCe without Pim-1 expression were ineffective.
ging: pseudocolor images representing signal intensity in mice treated with
nal was not detected 7 days after transplantation whereas hCPCeP-luc
eudocolor images represented in maximum radiance (p/s/cm2/sr). Abbrevia-I) ima
uc sig
of psPersistence of the BLI signal of hCPCeP until 2 months
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syngeneic CPCeP in mice (17) and supports the notion that
hCPCeP become permanently integrated into the myocar-
dium, unlike control hCPCe undetectable after 2 weeks
post-delivery. Moreover, the notably enhanced signal
from hCPCeP at 2 to 4 weeks after transfer coincides
with timing for recruitment of endogenous repair in the
infarcted heart (25). Increased presence of total c-kit cells
in the myocardium of hearts receiving hCPCeP (Figs. 4F to
4I) likely reflects augmentation of endogenous repair previ-
ously postulated to play a critical role in mediating myocar-
dial repair (39). The ensuing progressive loss of BLI signal
in hearts of recipient mice receiving hCPCeP over 2 months
could be caused by ongoing molecular and cellular processes
such as promoter silencing (29,40) or rejection of the
Figure 7 Echocardiography and MRI of Mice 8 Weeks After My
(A) Echocardiographic images from hCPCe-Luc and hCPCeP- Luc, (B) left ventricul
and (D) anterior wall (AW) thickness. Magnetic resonance imaging (MRI): (E) MRI
age (EF%), and (H) left ventricular end-systolic volume (LVESV). *p  0.05 versusallogenic human cells from remnants of non–T cell, non–Bcell immunity in the NOD/SCID mice (41). It is reasonable
to posit that persistence of hCPCeP could be further
improved with autologous transfer as well as by using
humanized expression vectors such as minicircles that can
persist for months in nondividing cells without integrating
into chromatin, thereby minimizing concerns of insertional
mutagenesis (42). Ongoing studies are evaluating minicircle
technology and other protocol modifications to further
refine the safety and efficacy of Pim-1 genetic engineering to
enhance myocardial regeneration.
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For an expanded Methods section and supplemental figures, please see the
online version of this article.
